Heart & Metabolic Health - Know your numbers
Cholesterol, ApoB and cardiovascular risk
Last updated 1 October 2026. How we write this .
Cholesterol measures the fat carried in blood particles; ApoB reflects how many potentially harmful particles circulate. Cardiovascular risk also depends on exposure over time and personal history.
Start here Cholesterol measures the fat carried in blood particles; ApoB reflects how many potentially harmful particles circulate. Cardiovascular risk also depends on exposure over time and personal history.
By the end, you will understand Cholesterol is cargo, lipoproteins are carriers How particles contribute to artery disease Reading the standard lipid panel Where this information comes from Claim-cited evidence. Central research claims on this lesson are linked to specific studies or official guidance.
This lesson links the specific studies and guidance used for its central claims.
Our standard: expert or athlete opinion may illustrate a viewpoint, but it is never treated as proof. Read the editorial policy .
Report an error or outdated claim .
Cholesterol and ApoB describe different aspects of the particles that can contribute to plaque in artery walls. LDL cholesterol measures the cholesterol carried inside LDL particles, while ApoB helps estimate the number of potentially harmful particles circulating. Neither gives a complete risk assessment: age, smoking, blood pressure, diabetes, kidney disease and family history change what a result means.
Cholesterol is cargo, lipoproteins are carriers
Cholesterol is essential for cell membranes and the production of several hormones and bile acids. Because it does not dissolve readily in blood, it travels inside packages called lipoproteins. These contain fats and proteins, with different classes carrying different mixtures of cholesterol and triglycerides.
LDL stands for low-density lipoprotein. LDL particles carry cholesterol between tissues, but they can also enter and become retained within artery walls. Calling LDL cholesterol "bad cholesterol" is convenient shorthand, although the cholesterol molecule itself is the same wherever it travels. The carrier and its behaviour matter.
Triglycerides are another type of fat, used mainly for energy storage and transport. The liver releases triglyceride-rich particles called VLDL. As their triglycerides are removed, smaller remnant particles form, some eventually becoming LDL. LDL and cholesterol-rich remnants both contribute to the burden of particles capable of promoting atherosclerosis.
How particles contribute to artery disease
Atherosclerosis begins when susceptible particles cross the artery's inner lining and become trapped in its wall. Retained particles can undergo changes that attract immune cells. Some immune cells take up their cholesterol and become foam cells, helping establish an inflammatory plaque.
Over time, plaques can contain cholesterol, immune cells, scar-like tissue and calcium. Some gradually narrow an artery. Others cause an acute problem when their surface ruptures or erodes and a blood clot forms. A clot can suddenly obstruct blood flow to the heart or brain.
This is why cardiovascular risk is not simply a question of whether blood is "too fatty". Particle entry, retention, the artery's response and clot formation all matter. Smoking, raised blood pressure and diabetes influence parts of this process without making cholesterol-containing particles irrelevant.
Exposure also accumulates. A moderately raised particle burden lasting decades can matter even when someone's short-term risk is low. A blood result is a snapshot of current circulation, not a measurement of lifetime exposure or a direct picture of existing plaque.
Reading the standard lipid panel
A lipid panel separates several related measurements. Understanding what each describes prevents a reassuring result in one column from obscuring a concern in another.
Total cholesterol includes cholesterol carried in several particle classes. On its own, it cannot distinguish their different contributions. LDL cholesterol estimates the cholesterol carried by LDL particles. Laboratories often calculate it; accuracy can become less reliable when triglycerides are substantially raised. Non-HDL cholesterol is total cholesterol minus HDL cholesterol. It captures cholesterol across the main potentially harmful particle classes, including LDL and remnants. HDL cholesterol measures cholesterol carried in HDL particles. It is associated with cardiovascular risk but does not directly measure how effectively HDL performs its functions. Triglycerides reflect energy-carrying fats. Meals, alcohol, metabolism, genetics and some medical conditions can influence the result. Many routine lipid assessments do not require fasting. However, unusual results or markedly raised triglycerides may need clarification through clinical review and further testing. Small differences between two panels can reflect normal biological variation or measurement differences rather than a meaningful change.
A laboratory reference range is also different from an individual risk-based goal. The same LDL cholesterol result can have different implications for someone with established cardiovascular disease and someone without it. Results belong alongside medical history, rather than being interpreted through coloured flags alone.
What ApoB and lipoprotein(a) add
Apolipoprotein B, usually shortened to ApoB, is a structural protein on potentially harmful lipoprotein particles. Each LDL, VLDL and remnant particle carries one ApoB molecule. Measuring its concentration therefore provides an estimate of particle number, rather than the amount of cholesterol those particles contain.
The distinction matters because cholesterol cargo varies. Two people can have similar LDL cholesterol but different numbers of LDL particles. This mismatch, often called discordance, can occur with raised triglycerides, insulin resistance or diabetes. ApoB may reveal a greater particle burden than LDL cholesterol alone suggests.
Large observational studies and genetic analyses support ApoB as a useful marker of atherosclerotic risk, particularly when measurements disagree. However, most major prevention trials have not directly compared an ApoB-led testing strategy with an LDL-led strategy. A useful marker is not automatically proof that routinely measuring it improves outcomes for everyone.
Lipoprotein(a), or Lp(a), is an LDL-like particle with an additional protein attached. Its concentration is largely inherited. Population studies and genetic evidence support its contribution to cardiovascular risk and narrowing of the aortic valve. It can help explain risk that a routine panel or family history does not fully capture.
ApoB and Lp(a) answer different questions. ApoB estimates the overall number of potentially harmful particles; Lp(a) identifies a particular inherited source of risk. Neither test directly shows whether an artery contains plaque.
What the evidence actually establishes
The case that LDL contributes causally to atherosclerosis rests on several types of evidence agreeing. Laboratory and animal work explain plausible mechanisms. Observational studies connect greater exposure with more events. Genetic studies associate lifelong differences in LDL with differences in risk, while large randomised trials show that lowering LDL can reduce cardiovascular events.
Each type has limits. Observational findings can be distorted by other differences between people. Genetic studies represent lifelong exposure and cannot precisely predict the effect of a shorter intervention. Trials provide stronger evidence about specific interventions in the populations studied, but their findings still need interpretation for individuals.
HDL illustrates why association is insufficient. Higher HDL cholesterol has often been associated with lower risk in population studies, yet trials of interventions designed to raise it have not consistently improved cardiovascular outcomes. A higher HDL result does not cancel out an elevated LDL or ApoB result.
Likewise, a claim about larger, supposedly harmless LDL particles oversimplifies the biology. Larger LDL particles can still contribute to atherosclerosis. Particle size does not provide a sound reason to dismiss a high particle burden.
Who needs a different interpretation
Risk calculators combine several characteristics to estimate the chance of an event over a specified period. NICE recommends QRISK3 for many UK adults without established cardiovascular disease. Such estimates support discussion; they do not predict exactly what will happen to one person.
In England, adults aged 40 to 74 without certain existing conditions, such as heart disease, diabetes or kidney disease, should be invited for a free NHS Health Check every five years. It usually includes a cholesterol test and a cardiovascular risk assessment. Arrangements differ in Scotland, Wales and Northern Ireland.
Age strongly influences short-term estimates. A younger adult can have a low calculated risk despite substantial lifetime exposure ahead. Conversely, an older adult's higher absolute risk means that a similar relative reduction in risk may translate into a larger absolute benefit.
Routine calculators are not appropriate for every situation. Established cardiovascular disease, familial hypercholesterolaemia and certain kidney conditions require different clinical assessment. Familial hypercholesterolaemia is an inherited condition associated with high LDL from early life; fitness or a balanced diet does not exclude it.
Persistent abnormalities may also reflect thyroid, kidney or liver conditions, or medicine effects. People with diabetes should interpret results with their diabetes care team. A consumer device or home result is not a basis for changing medicines.
Judging claims and prevention discussions
Lifestyle and medication discussions belong within an assessment of overall risk. Dietary patterns, activity and smoking influence cardiovascular health through several pathways, so their value cannot be judged solely by a change in LDL. Equally, favourable fitness or blood sugar results do not make a high ApoB result meaningless.
Statins and other cholesterol-lowering medicines are prescription-only in the UK. Whether to start, stop or change one is a decision made with a GP or pharmacist, based on overall risk, and nothing in this lesson is a reason to do any of those things.
Evidence from controlled feeding studies shows that replacing saturated fats with unsaturated fats generally lowers LDL cholesterol. Longer-term cardiovascular outcome evidence is harder to interpret because dietary changes overlap and adherence varies. Claims about one food need more caution than claims supported across several study types.
Ask what was measured: cholesterol concentration, particle number, plaque, or actual cardiovascular events. Separate relative benefit from absolute benefit. The same proportional reduction can mean different benefits at different starting risks. Check who was studied and for how long. Findings in a selected high-risk group may not transfer directly to everyone. Be cautious when a claim relies on testimonials, one biomarker, or a mechanism without human outcome evidence. Symptoms are a separate question
High cholesterol usually causes no symptoms, and a reassuring lipid panel cannot rule out an urgent heart problem. Stop activity if chest pain or sudden unexplained breathlessness develops. Call 999 for persistent chest pressure or pain, particularly with sweating, sickness, breathlessness or pain spreading to the arm or jaw. Contact a GP for chest pain that comes and goes, or NHS 111 if urgent assessment is needed and you are unsure what to do.
This lesson is general education, not medical advice. Seek qualified advice if you have symptoms or a medical condition, are pregnant, or take regular medicines.
Related in this classroom Related in other classrooms The studies behind this page Recommendations: cardiovascular risk assessment and lipid modification - NICE guideline NG238, reviewed 2025Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic and clinical studies - European Heart Journal, 2017Sources for this classroom
Educational content only. Not medical advice, diagnosis or treatment. Always consult a qualified healthcare professional before changing your health regimen.